Membrane News and Research

RSS

Growth, adaptation and neutralization of SARS-CoV-2 with acute-phase serum

One recent study published on the preprint server bioRxiv in June 2020 reports the results of growing and characterizing the virus, as well as the development of neutralizing antibodies in the serum of acutely infected hospitalized patients with COVID-19.

22 Jun 2020

Researchers produce first fully-glycosylated full-length SARS-CoV-2 spike protein models

The virus SARS coronavirus 2 (SARS-CoV-2) is the known cause of coronavirus disease 2019 (COVID-19). The "spike" or S protein facilitates viral entry into host cells.

22 Jun 2020

Research explores the biophysical behavior of SARS-CoV-2 nucleocapsid protein

In a groundbreaking paper currently available on the bioRxiv* preprint server, the researchers from the Washington University School of Medicine and Stony Brook University showed how nucleocapsid protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is dynamic, disordered and phase separates with RNA – informing, in turn, the discovery of drugs that disrupt viral packaging.

21 Jun 2020

Promising candidate monoclonal antibodies show "exquisite potency" against SAR-CoV-2

Researchers at Columbia University, Dana-Farber Cancer Institute, and the National Institutes of Health have identified and characterized a range of monoclonal antibodies that potently neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

21 Jun 2020

Direct structural link between SARS-CoV-2 and essential fatty acid

Now, a new study published on the preprint server bioRxiv in June 2020 reports the discovery of a novel free fatty acid (FFA) binding pocket on the SARS-CoV-2 virus that could explain in part the viral effects of hyperinflammation, immune modulation, and membrane structure.

21 Jun 2020

Nanosponges attract coronavirus away from lung cells, study shows

Imagine if scientists could stop the coronavirus infection in its tracks simply by diverting its attention away from living lung cells? A new therapeutic countermeasure, announced in a Nano Letters study by researchers from Boston University's National Emerging Infectious Diseases Laboratories and the University of California San Diego, appears to do just that in experiments that were carried out at the NEIDL in Boston.

18 Jun 2020

Conjunctivitis and keratoconjunctivitis can be possible primary symptoms of COVID-19

A case of pink eye is now reason to be tested for COVID-19, according to University of Alberta researchers.

18 Jun 2020

Cyclosporin study may pave way for treating diseases related to mitochondrial dysfunction

Cyclic peptide molecules of the fungal origin called cyclosporins were discovered in 1970's, and cyclosporin A soon became an important drug due to its immunosuppressive activity.

18 Jun 2020

First genome-wide CRISPR screen reveals genes that control SARS-CoV-2 infection

By performing a genome-wide CRISPR screen on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), U.S. researchers identified novel proviral genes and pathways, and highlighted host genes that may regulate coronavirus disease (COVID-19) pathogenesis, as well as revealing potential targets for novel treatment approaches. Their findings are currently available on the bioRxiv* preprint server.

18 Jun 2020

Scientists use CRISPR tool to make rapid, precise cuts in genomic material

In a series of experiments using human cancer cell lines, scientists at Johns Hopkins Medicine say they have successfully used light as a trigger to make precise cuts in genomic material rapidly, using a molecular scalpel known as CRISPR, and observe how specialized cell proteins repair the exact spot where the gene was cut.

18 Jun 2020

Study paints clear picture of how a protein that calms brain activity works

As the body goes about its daily business, molecules called neurotransmitters control the level of electrical activity within the brain.

17 Jun 2020

Researchers use cellular nanosponges to soak up SARS-CoV-2

Scientists are working overtime to find an effective treatment for COVID-19, the illness caused by the new coronavirus, SARS-CoV-2.

17 Jun 2020

UConn researchers tackle a vexing problem in the development of vaccines

Researchers at UConn's Center of Excellence in Vaccine Research have made a breakthrough in vaccine development for a common and difficult to treat pneumonia-causing pathogen. Their research was recently published in the Nature Partner Journal - Vaccines.

17 Jun 2020

Nanosponges could attack and neutralize SARS-COV-2 virus

Nanoparticles cloaked in human lung cell membranes and human immune cell membranes can attract and neutralize the SARS-CoV-2 virus in cell culture, causing the virus to lose its ability to hijack host cells and reproduce.

17 Jun 2020

How antibodies neutralize SARS-CoV-2 in convalescent patients

A new study by researchers from the United Kingdom and Taiwan and published on the preprint server bioRxiv in June 2020 describes the structural basis for the neutralizing effect of the SARS-CoV-2 antibody on the virus. This also indicates a possible therapeutic molecule by identifying its binding epitope as possibly a major neutralizing site.

16 Jun 2020

Link between ALS and Alzheimer's disease can help advance the search for new therapies

On the surface, amyotrophic lateral sclerosis (ALS) and Alzheimer's disease share two commonalities: Both are progressively debilitating neurodegenerative conditions--meaning symptoms get worse--and, at least for now, neither has an effective treatment, let alone a cure.

16 Jun 2020

Study reports structure of enzyme activator for high pathogenic avian influenza

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing the current pandemic of COVID-19, is the focus of many investigators seeking to find an effective vaccine or therapeutic. Among the potential targets are various protease enzymes suspected of allowing the virus to gain entry to host cells and establish a successful infection.

16 Jun 2020

SARS-CoV-2 mutation reduces S1 shedding, increases infective potential

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the seventh coronavirus known to infect humans. SARS-CoV-2 emerged in the last month of 2019 in Wuhan, China, sparking off the ongoing COVID-19 pandemic. This virus enters the host cells through receptor binding and membrane fusion between the viral and host cell membrane.

16 Jun 2020

Newfound knowledge may prove valuable to understand human nerve cells

Researchers discover what's behind nature's perhaps largest erection - which is not that big PLANT BIOLOGY.

16 Jun 2020

Millimeter-thick cell-laden hydrogel fiber helps control blood glucose in diabetic mice

Type 1 diabetes mellitus results from an irreversible autoimmune destruction of insulin-producing pancreatic β-cells requiring life-long substitution of insulin.

15 Jun 2020